VR Adviser’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-369,306
Closed -$4.72M 29
2022
Q3
$4.72M Hold
369,306
0.73% 24
2022
Q2
$4.32M Sell
369,306
-390,413
-51% -$2.41M 0.85% 23
2022
Q1
$4.63M Buy
+759,719
New +$5.59M 0.75% 23
2021
Q4
Sell
-3,800,000
Closed -$43M 27
2021
Q3
$43M Buy
3,800,000
+300,000
+9% +$3.65M 5.52% 6
2021
Q2
$34.5M Hold
3,500,000
4.18% 9
2021
Q1
$49.5M Sell
3,500,000
-1,000,000
-22% -$16.2M 5.37% 5
2020
Q4
$50.8M Hold
4,500,000
7.46% 6
2020
Q3
$59.4M Hold
4,500,000
11.62% 3
2020
Q2
$48.2M Buy
+4,500,000
New +$24.7M 11.54% 3

Other funds holding ALT

VR Adviser's ALT Position: Q4 2022 in Review

VR Adviser sold out of Altimmune (ALT) in Q4 2022, closing a stake of 369,306 shares — an estimated $4.72M sold.

VR Adviser first reported a position in ALT in Q2 2020 and held it in 9 quarters. The position peaked at $59.4M in Q3 2020. 128 funds tracked by Wall St. Rank hold ALT as of Q4 2022.

  • VR Adviser reported no remaining Altimmune position as of Q4 2022 after selling out during the quarter.
  • VR Adviser sold 369,306 Altimmune shares in Q4 2022, an estimated $4.72M.
  • VR Adviser first reported a position in Altimmune in Q2 2020 and held it in 9 quarters.
  • VR Adviser's Altimmune position peaked at $59.4M in Q3 2020.
  • 128 funds tracked by Wall St. Rank held Altimmune as of Q4 2022.

Based on VR Adviser's 13F filing for Q4 2022, filed 14 Feb 2023.